Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
Autonomix Medical (NASDAQ: AMIX) will present final clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at the SIO 2026 Annual Scientific Meeting in Savannah, GA (Feb 4-8, 2026).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) will present final clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at the SIO 2026 Annual Scientific Meeting in Savannah, GA (Feb 4-8, 2026).
The ePoster (Abstract #327) will be presented by Clarke Wilkirson, PhD on Feb 6, 2026, 5:30–6:30 PM EST, including a 10-minute talk and 5-minute discussion during the Science and Sips reception.
Details
News Market Reaction – AMIX
On Jan 28, the day this news came out, AMIX closed 0.14% below the previous close.
Data tracked by StockTitan Argus for the Jan 28 session.
Key Figures
- Quarterly net loss
- $7.5 million
- Net loss for quarter ended Sep 30, 2025 (Q2 FY2026)
- Six-month net loss
- $10.8 million
- Net loss for six months ended Sep 30, 2025
- Cash balance
- $7.5 million
- Cash and cash equivalents at Sep 30, 2025
- Equity purchase agreement
- $15.0 million
- Equity purchase agreement with Lincoln Park
- ATM gross proceeds
- $2.6 million
- ATM sales fiscal-to-date through Q2 FY2026
- PIPE gross proceeds
- $5.0 million
- November 2025 PIPE transaction
- Potential warrant proceeds
- $7.7 million
- If all Common Warrants are exercised in cash
- Warrants registered
- 13,504,998 shares
- Shares underlying warrants on S-3 shelf
Historical Context
-
ASCO GI subgroup data showing rapid, durable pain relief across disease stages.
-
European patent granted on cardiac neuromodulation platform technology.
-
CEO outlined IP strengthening and multi-indication expansion strategy.
-
ASCO GI 2026 poster acceptance on long-term pancreatic pain mitigation data.
-
CEO Corner discussing IP protection and expansion beyond pancreatic cancer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
transvascular radiofrequency (RF) ablation medical
pancreatic adenocarcinoma medical
neurolysis medical
interventional oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting happening February 4-8, 2026 in Savannah, GA.
The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation,” has been accepted as an ePoster presentation for the conference’s Science and Sips Reception, highlighting emerging innovations in interventional oncology.
The ePoster (Abstract #327) will be presented by Clarke Wilkirson, PhD on Friday, February 6, 2026, from 5:30 PM to 6:30 PM EST, in the ePoster corridor outside the exhibit hall. As part of the Science and Sips program, the presentation will include a dedicated 15-minute session consisting of a 10-minute presentation followed by a 5-minute discussion period.
“Pain remains one of the most debilitating and difficult-to-treat complications for patients with pancreatic cancer,” said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. “We are pleased to present the final analysis of this study at the SIO 2026 Annual Scientific Meeting, as it highlights the potential of our transvascular RF ablation approach to address a significant unmet clinical need. We believe this minimally invasive therapy may offer a meaningful opportunity to improve pain control and quality of life for patients facing this devastating disease.”
The SIO Annual Scientific Meeting brings together leading clinicians, researchers and innovators focused on advancing minimally invasive, image-guided therapies for cancer care. For more details, please visit the conference website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.